Cellectar Biosciences Company Profile (NASDAQ:CLRB)

About Cellectar Biosciences

Cellectar Biosciences logoCellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLRB
  • CUSIP:
Key Metrics:
  • Previous Close: $2.42
  • 50 Day Moving Average: $1.58
  • 200 Day Moving Average: $2.02
  • 52-Week Range: $5,368,000.00 - $1.00
  • Trailing P/E Ratio: 5.04
  • Foreward P/E Ratio: -2.75
  • P/E Growth: 0.00
  • Market Cap: $27.83B
  • Outstanding Shares: 5,368,000
  • Beta: 0.58
Profitability:
  • Return on Equity: -48.85%
  • Return on Assets: -31.41%
Debt:
  • Current Ratio: 4.32%
  • Quick Ratio: 4.32%
Additional Links:
Companies Related to Cellectar Biosciences:

Analyst Ratings

Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.70 (11.57% upside)

Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)
Show:
DateFirmActionRatingPrice TargetDetails
12/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$2.70View Rating Details
12/21/2016Langenberg & CompanyInitiated CoverageBuy$2.70View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/12/2015Q315($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.30)ViewListenView Earnings Details
5/21/2015Q115($0.30)ViewListenView Earnings Details
3/26/2014($0.04)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.40)($0.40)($0.40)
Q3 20161($0.20)($0.20)($0.20)
Q4 20161($0.20)($0.20)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectar Biosciences (NASDAQ:CLRB)
Insider Ownership Percentage: 15.45%
Institutional Ownership Percentage: 1.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016John NeisDirectorBuy333,333$1.49$496,666.17View SEC Filing  
10/31/2016Richard HertzbergInsiderSell21,000$2.03$42,630.00View SEC Filing  
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.76View SEC Filing  
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52View SEC Filing  
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.00View SEC Filing  
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.00View SEC Filing  
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.00View SEC Filing  
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
DateHeadline
News IconAnalyst Advice And Earnings Insight: Century Aluminum Company (CENX), Cellectar Biosciences, Inc. (CLRB) - Post Analyst (NASDAQ:CLRB)
postanalyst.com - February 17 at 5:51 PM
News IconCellectar Biosciences, Inc. (CLRB): Essential Chart Information - NY Stock News (NASDAQ:CLRB)
nystocknews.com - February 17 at 5:51 PM
News IconCellectar Biosciences Inc (NASDAQ:CLRB) Still Has Plenty Of Run Room - Insider Financial (NASDAQ:CLRB)
www.insiderfinancial.com - February 17 at 5:51 PM
News IconMarket Review: Indicator Watch for Cellectar Biosciences Inc. (CLRB) - Rives Journal (NASDAQ:CLRB)
rivesjournal.com - February 14 at 5:09 PM
News IconCellectar Biosciences, Inc. NASDAQ:CLRB Sees High Volatility in Session - Aiken Advocate (NASDAQ:CLRB)
aikenadvocate.com - February 14 at 5:09 PM
News IconStock Overbuying in Action: Cellectar Biosciences Inc (NASDAQ:CLRB) - Post Registrar (NASDAQ:CLRB)
postregistrar.com - February 14 at 5:09 PM
finance.yahoo.com logoUPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference (NASDAQ:CLRB)
finance.yahoo.com - February 13 at 5:01 PM
finance.yahoo.com logoCellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma (NASDAQ:CLRB)
finance.yahoo.com - February 13 at 5:01 PM
News IconShare Levels in Review for Cellectar Biosciences Inc. (CLRB) - Davidson Register (NASDAQ:CLRB)
davidsonregister.com - February 11 at 2:39 AM
finance.yahoo.com logoCellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference (NASDAQ:CLRB)
finance.yahoo.com - February 9 at 4:44 PM
News IconStock Moving Up in Today's Session: Cellectar Biosciences, Inc.(NASDAQ:CLRB) - Aiken Advocate (NASDAQ:CLRB)
aikenadvocate.com - February 7 at 5:25 PM
News IconEquity Focus: Indicator Check on Shares of Cellectar Biosciences Inc. (CLRB) - Rives Journal (NASDAQ:CLRB)
rivesjournal.com - February 7 at 5:25 PM
globenewswire.com logoCellectar Biosciences to Present at 2017 BIO CEO & Investor Conference - GlobeNewswire (press release) (NASDAQ:CLRB)
globenewswire.com - February 7 at 5:25 PM
feeds.benzinga.com logoCellectar Biosciences to Present at 2017 BIO CEO & Investor Conference (NASDAQ:CLRB)
feeds.benzinga.com - February 7 at 9:19 AM
News IconCellectar Biosciences Inc CLRB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CLRB)
www.bioportfolio.com - February 5 at 4:18 PM
News IconTrading Insight: Taking a Look at Levels for Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - February 2 at 9:43 PM
News IconTwo studies demonstrate capabilities of phospholipid drug conjugates (NASDAQ:CLRB)
www.dotmed.com - February 1 at 4:39 PM
News IconBoom or Bust? Is there any value in Cellectar Biosciences, Inc ... - Prospect Journal (NASDAQ:CLRB)
prospectjournal.com - February 1 at 4:47 AM
News IconPlacing This Stock in the Hotbed: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Prospect Journal (NASDAQ:CLRB)
prospectjournal.com - February 1 at 4:47 AM
smarteranalyst.com logoStock Update (NASDAQ:CLRB): Cellectar Biosciences Inc Announces Two Peer Reviewed Studies Demonstrating the ... - Smarter Analyst (NASDAQ:CLRB)
www.smarteranalyst.com - February 1 at 4:47 AM
investingnews.com logoCellectar Biosciences Demonstrates Capabilities of the PDC Platform in Two Peer Reviewed Studies (NASDAQ:CLRB)
investingnews.com - January 31 at 4:48 PM
finance.yahoo.com logoCellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform (NASDAQ:CLRB)
finance.yahoo.com - January 31 at 4:48 PM
finance.yahoo.com logo8:35 am Cellectar Biosciences announces the advance online publication of an article in Nature Reviews Clinical Oncology and a presentation on its drug delivery platform at the Academic Surgical Congress on February 8, 2017 (NASDAQ:CLRB)
finance.yahoo.com - January 31 at 4:47 PM
News IconCellectar Biosciences, Inc. (NASDAQ:CLRB) Announces Additional US Patents Granted as Share Price Advances on ... - Nelson Observer (NASDAQ:CLRB)
nelsonobserver.com - January 28 at 4:34 PM
News IconAverage Directional Index Review for Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 27 at 5:43 PM
News IconEarnings in Full Force, Analysts Take Aim at Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Wall Street Beacon (NASDAQ:CLRB)
wsbeacon.com - January 26 at 5:22 PM
News IconRange Watch on Technical Indicators for Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 26 at 5:22 PM
smarteranalyst.com logoStock Update (NASDAQ:CLRB): Here's Why Cellectar Biosciences Inc Shares Are Rising 15% - Smarter Analyst (NASDAQ:CLRB)
www.smarteranalyst.com - January 26 at 5:22 PM
globenewswire.com logoCellectar Biosciences to Present at NobleCon13 - GlobeNewswire (press release) (NASDAQ:CLRB)
globenewswire.com - January 26 at 5:22 PM
feeds.benzinga.com logoCellectar Biosciences to Present at NobleCon13 (NASDAQ:CLRB)
feeds.benzinga.com - January 26 at 9:17 AM
News IconFocus on RSI and CCI Levels: Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 26 at 3:31 AM
News IconEnlivened Volatility Spotted in Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Wall Street Beacon (NASDAQ:CLRB)
wsbeacon.com - January 26 at 3:31 AM
us.rd.yahoo.com logo8:32 am Cellectar Biosciences: USPTO has granted patent covering method of use for its lead compound, CLR 131, as well as CLR 125, for the treatment of cancer (NASDAQ:CLRB)
us.rd.yahoo.com - January 25 at 10:28 PM
News IconCellectar Biosciences granted additional US patent for CLR 131 and CLR 125 in solid tumours (NASDAQ:CLRB)
www.dotmed.com - January 25 at 5:27 PM
investopedia.com logoCellectar Gets Another Cancer Drug Patent (CLRB) (NASDAQ:CLRB)
www.investopedia.com - January 25 at 5:27 PM
investopedia.com logoCellectar Biosciences Secures Cancer Drug Patent (NASDAQ:CLRB)
www.investopedia.com - January 25 at 5:27 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Automakers, Verizon ... - Nasdaq - Nasdaq (NASDAQ:CLRB)
www.nasdaq.com - January 24 at 9:57 PM
News IconInvestor Notebook: Focusing in on Shares of Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 24 at 9:57 PM
streetinsider.com logoCellectar Biosciences (CLRB) Announces US Patent Granted for CLR 131 and CLR 125 - StreetInsider.com (NASDAQ:CLRB)
www.streetinsider.com - January 24 at 9:57 PM
investing.com logoCellectar Biosciences Inc (CLRB) (NASDAQ:CLRB)
www.investing.com - January 24 at 4:56 PM
streetinsider.com logoCellectar Biosciences (CLRB) Announces US Patent Granted for CLR 131 and CLR 125 (NASDAQ:CLRB)
www.streetinsider.com - January 24 at 4:56 PM
us.rd.yahoo.com logoCellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors (NASDAQ:CLRB)
us.rd.yahoo.com - January 24 at 4:56 PM
News IconPeculiar Activity & Volume Noted in Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Aiken Advocate (NASDAQ:CLRB)
aikenadvocate.com - January 23 at 9:39 PM
News IconPriming The Pump: Stock Volatility Spotted in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Wall Street Beacon (NASDAQ:CLRB)
wsbeacon.com - January 23 at 9:39 PM
News IconStock Going Gangbusters Mid-Session: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Wall Street Beacon (NASDAQ:CLRB)
wsbeacon.com - January 23 at 9:39 PM
biz.yahoo.com logoCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CLRB)
biz.yahoo.com - January 22 at 2:26 AM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Aiken Advocate (NASDAQ:CLRB)
aikenadvocate.com - January 21 at 9:24 PM
News IconTrading Indicator Check on Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 20 at 10:31 PM
News IconPopping up on Watch-lists are Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Prospect Journal (NASDAQ:CLRB)
prospectjournal.com - January 20 at 10:31 PM
News IconKeeping Tabs on Technicals for Cellectar Biosciences Inc. (CLRB) - Sherwood Daily (NASDAQ:CLRB)
sherwooddaily.com - January 20 at 3:38 AM

Social

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Where is Cellectar Biosciences' stock going? Where will Cellectar Biosciences' stock price be in 2017?

2 brokers have issued 12-month price targets for Cellectar Biosciences' shares. Their predictions range from $2.70 to $2.70. On average, they expect Cellectar Biosciences' stock price to reach $2.70 in the next twelve months.

When will Cellectar Biosciences announce their earnings?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

How do I buy Cellectar Biosciences stock?

Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cellectar Biosciences stock cost?

One share of Cellectar Biosciences stock can currently be purchased for approximately $2.42.

Cellectar Biosciences (NASDAQ:CLRB) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Earnings History Chart

Earnings by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Dividend History Chart

Dividend Payments by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Last Updated on 2/20/2017 by MarketBeat.com Staff